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ABSTRACT
Objectives: The Joint Commission revised its National
Patient Safety Goals (NPSGs) to include oral
anticoagulation therapy (OAT) in 2008. We sought to
examine the effect of including OAT in The Joint
Commission’s NPSGs on historically low rates of
OAT initiation for individuals with incident atrial
fibrillation (AF).
Setting: Southeastern state in the USA.
Participants: North Carolina State Health Plan claims
data from 944 500 individuals enrolled between
1 January 2006 and 31 December 2010, supplemented
with data from the Area Resource File and Online
Survey, Certification and Reporting data network.
We evaluated OAT initiation before and after the 2008
NPSGs revisions in a retrospective cohort new user
design with an AF intervention group and two control
groups: a positive control—patients estimated to be at
very high risk of thromboembolism (mechanical heart
valve and pulmonary embolism); and a negative control
—patients with very low perceived risk of
thromboembolism (paroxysmal AF). We developed
multivariable models using a difference-in-difference
parameterisation. Effects were estimated with
generalised estimating equations.
Primary outcome measure: OAT initiation, a binary
outcome defined as having a prescription drug claim
for warfarin within 30 days of the index claim.
Results: OAT initiation was low (26.8%) for eligible
individuals with incident AF in 2006–2008 but
increased after NPSGs implementation (31.7%,
p=0.022). OAT initiation was high but decreased in the
positive control group (67.5% vs 62.0%, p=0.003).
Multivariate analysis resulted in a relative 11% (95% CI
(4% to 18%), p<0.01) increase in OAT initiation for
incident AF patients.
Conclusions: We document a substantial increase in
guideline concordant OAT initiation in incident AF after
the establishment of NPSGs, suggesting that regulatory
healthcare agency initiatives can influence clinical
practice.
BACKGROUND
Oral anticoagulation therapy (OAT) to
reduce acute ischaemic stroke risk in patients
with moderate-risk or high-risk atrial
fibrillation (AF), typically with warfarin, has
been recommended by guidelines from
major organisations for nearly two decades.1
However, despite its benefit, OAT is often
underutilised among eligible patients with
AF.2–8 Underutilisation may result from
patient, physician and/or healthcare system
factors.9–15
The Joint Commission is the nation’s
oldest and largest standards-setting and
accrediting body in healthcare. Its primary
purpose is to16: “continuously improve
healthcare for the public, in collaboration
with other stakeholders, by evaluating health-
care organisations and inspiring them to
excel in providing safe and effective care of
the highest quality and value”. To this end,
the Joint Commission evaluates and accredits
more than 19 000 healthcare organisations
and programmes in the USA. The Joint
Commission accreditation is required for
reimbursement from Medicare and many
private health insurance companies. The
Joint Commission established a National
Patient Safety Goals (NPSGs) programme in
2002 to help accredited organisations
address specific patient safety concerns. To
oversee this task, it established the Patient
Safety Advisory Group, a panel of nurses,
physicians, pharmacists, risk managers, clin-
ical engineers and other professionals who
Strengths and limitations of this study
▪ Privately insured cohort with 5 years claims data,
extensive control variables and two control
groups.
▪ Claims analysis; lacks individual race/ethnicity
and socioeconomic status information; may not
generalise to public insurance programmes (eg,
Medicaid and Medicare).
▪ Non-experimental, pre–post two-group compari-
son design means that results cannot be inter-
preted as causal.
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have hands-on experience in addressing patient safety
issues in a wide variety of healthcare settings. This panel
continuously evaluates and updates NPSGs to identify,
prioritise and help address a broad range of emerging
patient safety issues.
In 2008, the NPSGs were updated to include goals
regarding OAT. The NPSGs concerning anticoagulation
(specifically, NPSG 03.05.01) represent a change in the
external environment, or natural experiment, intended
to affect the healthcare system, most notably hospitals.
They do not mandate that all eligible patients receive
anticoagulation, but rather provide explicit guidelines
and expectations for hospitals that provide anticoagula-
tion therapy and/or long-term OAT to reduce the likeli-
hood of patient harm associated with these therapies.
Achieving compliance with NSPGs may be moderated
by a hospital’s pre-existing resources and practice norms,
as well as their willingness to invest in the infrastructure
required to meet them. Hospitals with sufficient
resources may be in compliance with regulatory require-
ments before or soon after they are established. Hospitals
with fewer resources may take longer to become compli-
ant with new regulatory requirements or attempt to avoid
them altogether. In the case of OAT, hospitals may invest
in resources to provide long-term outpatient manage-
ment and monitoring for patients receiving OAT, for
example, anticoagulation clinics. Providing anticoagula-
tion clinics is thought to increase OAT initiation and
OAT quality as community admitting physicians may be
more likely to initiate OAT due to hospital regulatory
requirements and the availability of additional resources
to manage and monitor anticoagulation.14 17
However, hospitals may instead opt to minimise use of
anticoagulants, discontinue anticoagulation clinics and
elect not to initiate OAT in eligible patients, in the hope of
avoiding increasing regulatory oversight and burden of
compliance. In this case, hospital actions negatively influ-
ence OAT initiation via establishing clinical inertia (eli-
gible patients often start OAT as inpatients) and the
NPSGs (intended to prevent harm) may have an unin-
tended effect in reducing OAT initiation for eligible
patients. The precedent of newly developed policy achiev-
ing its proximal intended effects while creating larger
downstream unintended effects is well-established. For
example, pay-for-performance and organisational quality
reporting initiatives have been met with unintended conse-
quences in the experience of several countries.18–21 This
can include unintended consequences of increased
healthcare costs,22 reduced quality of unreported care21
and lower quality care among highest risk patients.18 20
Similarly, public reporting of outcomes data by provider
for cardiac surgery in New York state led to subsequent
high-risk patient aversion and higher cardiac surgery mor-
tality rates in neighbouring states.23 Finally, the Center for
Medicare and Medicaid Services (CMS) recently imple-
mented a policy to withhold payment to hospitals for
certain avoidable adverse events has also resulted in unin-
tended consequences.24
Although the implementation of NPSGs is intended to
improve healthcare quality (especially process-oriented
measures), the Joint Commission’s prior initiatives have
had mixed success. For example, compliance with the
Joint Commission guidelines for discharge instructions
in patients with heart failure was associated with
decreased readmission rates.25 Similarly, a positive rela-
tionship between adherence to the Joint Commission
heart failure core measures and 1-year survival has been
reported.26 However, other studies found no association
between adherence to the Joint Commission heart
failure core measures and mortality or readmission at
60–90 days or at 1 year.27 28
We sought to determine the effect of the Joint
Commission’s anticoagulation NPSGs on OAT initiation.
We hypothesised the NPSGs would increase OAT initi-
ation among eligible patients hospitalised with incident
AF, but were keenly aware of the potential unintended
negative influence of the NPSGs on OAT initiation. We
also conducted sensitivity analyses to examine potential
indirect effects of the NPSGs.
METHODS
Data sources
We used data from 1 January 2006 to 31 December 2010
from the North Carolina State Health Plan (NCSHP), a
large self-funded insurance plan for the study. The
NCSHP, administered by Blue Cross and Blue Shield of
North Carolina, includes almost 700 000 state employ-
ees, teachers, retirees and their dependents at any given
time and approximately one million individuals are
included in the 5-year study window. Approximately 10%
of enrollees are retired non-Medicare participants, and
16% are retired Medicare beneficiaries. This claims
structured database contains inpatient, outpatient and
pharmacy records. Enrollee descriptors include unique
encrypted member identification numbers, basic demo-
graphic information including age, gender, county and
Zone Improvement Plan (ZIP) code of primary resi-
dence. Records include information about diagnoses,
procedures, providers, charges and payments. The data-
base also contains physician level characteristics which
include provider ZIP code, type of provider and provider
specialty if applicable. We linked the NCSHP database to
hospital facility characteristics including accreditation as
a primary stroke centre, hospital bed size and participa-
tion in a stroke quality improvement programme.
Finally, we linked individual and facility counties with
variables from the Area Resource File to concurrently
analyse healthcare delivery at the patient, provider, hos-
pital facility and county levels.
Cohort selection rationale
Our goal was to create three cohorts with varying levels
of thromboembolism risk without receipt of OAT.
Specifically we sought to create perceived high, medium
and low thromboembolism risk cohorts, with the intent
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to use the high-risk and low-risk cohorts as positive and
negative control groups, respectively. The incidence of
thromboembolism in patients with mechanical heart
valves is 4.4/100 patient-years without anticoagulation
and 1.0/100 patient-years with warfarin.29 Although the
attributable risk of AF to ischaemic stroke increases dra-
matically with increasing age, the overall relative risk is
approximately fivefold higher for ischaemic stroke
among patients with AF.30 Including all ages, the average
annual risk of ischaemic stroke for individuals with AF is
2–4% per year (2–4 per 100 patient-years).29 OAT
reduces this risk by 64%.31 Historically paroxysmal
(intermittent) AF has been considered a lower risk for
ischaemic stroke than mechanical heart valves and
chronic AF.32 33 However, a signal of equivalent ischae-
mic stroke risk was apparent as early as 2000 in the
Stroke Prevention in AF trial.34 Yet despite others con-
firming the elevated risk associated with paroxysmal
AF,32 35 major guidelines for primary prevention of
stroke were not changed to include OAT for paroxysmal
AF until 2006.29 Thus our inclusion of paroxysmal AF as
a negative control group is based on historically per-
ceived risk rather than actual risk of ischaemic stroke.
Study sample
We created three cohorts: (1) patients with new onset
AF; (2) positive control patients who are estimated to be
at high risk of thromboembolism (mechanical heart
valve or significant venous embolism) and (3) negative
control patients, often mistakenly perceived to have a
very low risk of thromboembolism (paroxysmal AF). For
all three cohorts, patients needed to be continuously
enrolled in the NCSHP a minimum of 6 months prior to
and 6 months following the qualifying index claim.
Individuals with a prescription claim for warfarin more
than 30 days prior to an index claim for any of the three
cohorts were excluded due to a high probability of
representing prevalent rather than incident conditions.
Figure 1 provides a summary of cohort identification
and determination of eligibility. Eligibility criteria for
each cohort are described below.
Patients with new onset AF: We used either one
inpatient diagnosis or two outpatient diagnoses within
12 months (International Classification of Disease 9th
edition-Clinical Modification (ICD-9-CM) code 427.31)
to identify individuals with AF. We designated the first
outpatient AF claim or hospital admission as the date of
entry into the cohort. The American College of
Cardiology, the American College of Chest Physicians
and the American Heart Association endorse the use of
a risk-based score to identify individuals who will benefit
from receiving OAT. CHADS2 is a commonly employed
scoring system.36 Individuals receive one point for con-
gestive heart failure, hypertension, age >75 years, and
diabetes mellitus; they receive two points for any prior
stroke or stroke symptoms. CHADS2 scores are readily
generated using claims data (see web-only table A.1 for
ICD-9-CM codes for these diagnoses). Based on current
recommendations,31 we included all individuals meeting
criteria for incident AF with a CHADS2 score ≥2. To
increase the precision of our estimates, we used
ICD-9-CM codes to exclude individuals with ≥1 relative
contraindication to OAT from the incident AF or inter-
vention cohort (see web-only table A.2 for contraindica-
tions and ICD-9-CM codes). Finally, to reduce the
probability of including individuals with prevalent,
rather than incident, AF, we excluded individuals with
any AF-related claim in the 6 months preceding the
index claim.
Perceived very high-risk patients (positive controls):
this cohort includes individuals with either one inpatient
diagnosis or two outpatient diagnoses within 12 months
indicating a mechanical heart valve or significant
thromboembolism (see web-only table A.3 for diagnoses
and ICD-9-CM codes). The CHADS2 score was not
applied to this cohort, as it is only validated in patients
with AF. Finally, to reduce the probability of including
individuals with prevalent conditions rather than incident
mechanical heart valves or significant thromboembolism,
we excluded individuals with any condition-related claim
in the 6 months preceding the index claim.
Perceived low-risk patients (negative controls): indivi-
duals with either one inpatient diagnosis or two out-
patient diagnoses within 12 months for paroxysmal AF
(ICD-9-CM code 427.21) were included in the negative
control cohort.
Measures
The primary dependent variable is OAT initiation, a
binary outcome defined as having a prescription drug
claim for warfarin within 30 days of the index claim.
Index claims occurring in years 2006–2008 were
Figure 1 Selection of incident
atrial fibrillation (AF), application
of inclusion/exclusion criteria and
identification of comorbid
conditions. Key aspects of
defining eligibility period,
measurement of comorbid
conditions and measurement of
oral anticoagulation therapy
(OAT) initiation are shown above.
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categorised as pre-NPSGs; index claims in 2009–2010
were assigned post-NPSGs status. The key explanatory
variable is the interaction term between a binary indica-
tor for prestatus/poststatus of the Joint Commission’s
NPSGs and a binary indicator variable for the incident
AF cohort, which represents the difference-in-difference
estimator. The difference-in-difference estimator is the
pre–post difference in the treatment (AF cohort) group
minus the pre–post difference in the control group
(positive control cohort).
Control variables were created at the patient, county
and facility levels. All control variables were identified a
priori and measured in the baseline period or immedi-
ately prior to the index AF claim to mitigate potential
confounding. Patient-level control variables include age,
gender, Charlson Comorbidity Index,37 38 CHADS2
score, rurality/urbanicity of residence, and number of
outpatient visits to a primary care provider in the 30 days
prior to the index claim. The Charlson Comorbidity
Index, a widely used measurement of patient comorbid-
ities, was categorised as 0, 1, 2, 3–4 and ≥5. CHADS2
score was categorised as 2, 3–4 and ≥5. Rurality/urbani-
city of residence was categorised into rural, micropolitan
or metropolitan as defined by the Area Resource File.39
County-level control variables included: race and eth-
nicity demographics, unemployment rate, per cent of
persons below poverty line, median household income,
a rolling 3-year average number of deaths from cerebro-
vascular disease, number of general practitioners and
number of cardiovascular subspecialists in county, which
were extracted from the Area Resource File.39
We specifically included several facility-level variables
that were anticipated to have substantial influence in
OAT initiation rates. These facility level control variables
included: hospital primary stroke centre accreditation
status as defined by CMS (binary variable for each time
period); participation in ‘Get with the Guidelines
Stroke:’ Program or North Carolina Stroke Care
Collaborative, stroke care quality improvement pro-
grammes that include AF and OAT (binary variable for
each time period); distance of hospital from enrollee
residence; hospital bed size and rural/urban facility
location. Get with the Guidelines Stroke participation
was determined from the American Heart Association
website (http://www.heart.org). Participation in the
North Carolina Stroke Care Collaborative was provided
by the organisation. We calculated distance as the
straight line distance from the centroid of patient and
hospital ZIP codes using SAS V.9.2. Hospital bed size was
determined from the Online Survey, Certification and
Reporting (OSCAR) data network maintained by the
CMS.
Statistical analysis
We examined cohorts for differences in baseline covari-
ates as well as differences within cohorts between preper-
iod and postperiod. Unadjusted rates of OAT initiation
for each cohort were also examined. We then estimated
the association between NPSGs and initiation of OAT
among individuals with new onset AF using a
difference-in-difference approach and multivariable
regression equations. Differences in OAT initiation
before and after the policy change for the control
groups are attributed to a time effect. Subtracting the
pre–post difference in the positive control cohort from
the pre–post difference in the AF (treatment) cohort
yields an estimate that is more robust to external factors
and time effects. In practice the difference-in-difference
estimate is created by interacting the treatment (in this
case time) variable with a dummy variable indicating the
treatment cohort. Thus we model the probability of
OAT initiation using a log-Poisson model specified as:
Pr(OATift ¼ 1jXift) ¼ logXb ð1Þ
with
Xb ¼ b0 þ b1AFi þ b2Posti þ b3(AFi  Posti)þ b4Xi
where i indicates the individual, OAT is the outcome
variable, AF represents the cohort and Post indicates
whether the index claim occurred pre (Post=0) or post
(Post=1) NPSGs implementation, and X is a vector of
individual patient and facility control variables defined
above. Facility level fixed effects are taken into account
by clustering within facilities using the administrative
hospital identification number and specifying an
exchangeable within-group correlation structure. The
coefficient that identifies the effect of interest is β3,
which estimates the effect of NPSGs on the probability
of OAT initiation for patients with incident AF.
We estimated the parameters in the above model
robustly using generalised estimating equation (GEE)
methods in which we specified a Poisson error distribu-
tion. To account for within hospital correlation (eg,
observations within hospital are not completely inde-
pendent observations) we clustered on administrative
hospital identification number by specifying the cluster
variable during fitting of the GEE model and assumed
an exchangeable within-group working correlation struc-
ture.40 Robust (sandwich estimation) SEs were estimated
during model fitting, to account for underdispersion of
the binary dependent variable in the context of a count
distribution.41 We converted the coefficients to average
marginal effects as absolute risk differences for ease of
interpretation. All models were estimated in Stata V.11
(StataCorp, College Station, Texas, USA).
We conducted several sensitivity analyses. The first
assessed potential measurement error in OAT initiation.
The rise of many low-cost generic prescription drug pro-
grammes administered through major retailers has
caused concern regarding under identification of
generic drugs within pharmacy claims data.42 43
Warfarin has been generic for several decades, and mul-
tiple generic formulations exist. While a claim for war-
farin is specific for OAT initiation, it may be lacking
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somewhat in sensitivity. We created two alternative defini-
tions for OAT initiation using claims for laboratory
blood tests associated with blood coagulation or anticoa-
gulation management claims (see web-only table A.4 for
Current Procedural Terminology (CPT) codes and
ICD-9-CM codes employed). The laboratory blood tests
were hypothesised to represent a sensitive measure of
OAT initiation that might have less specificity for OAT
initiation as it is associated with the monitoring of the
effect of warfarin, but is not specific to anticoagulation
management alone.
The first alternative definition for OAT initiation com-
bined: a pharmacy claim for warfarin; a claim for asso-
ciated laboratory blood tests or a claim for OAT
management. The second alternative definition
excluded the pharmacy claim, utilising only the labora-
tory blood test and OAT management claims to define
initiation. The next sensitivity analysis compared the
effect of the policy on an inpatient only cohort
(hypothesised to demonstrate the greatest effect), an
outpatient only cohort, and a combined inpatient and
outpatient cohort. The final set of sensitivity analyses
involved an extensive evaluation of non-linear effects of
included model covariates and additional county level
covariates that could be hypothesised to affect the
observed relationship between the policy change and
observed OAT initiation rates.
RESULTS
Descriptive findings
We identified 2021 individuals for the AF cohort; 2708
individuals for the positive control cohort; and 606 indi-
viduals for the negative control cohort (table 1). Both
control groups exhibited a decrease in proportion initi-
ating OAT while the eligible AF cohort exhibited an
increase (0.268 vs 0.317). The relative OAT initiation
pre–post difference (change in intervention minus
change in control) for the eligible AF cohort was 0.104
and 0.081 in comparison to the positive and negative
controls, respectively. OAT initiation in the AF group
(26.8%) was within range of previous observational
studies.44
Within specific cohorts, age remained stable while
comorbidities increased in the postperiod (table 2). In
all cohorts, there was a marked increase in the
percentage of individuals treated in hospitals that were
accredited primary stroke centres or participating in a
quality improvement programme for acute stroke care.
County level characteristics generally remained stable
from the preperiod to postperiod. Two notable excep-
tions to this trend were average unemployment rate and
per cent of persons in poverty, which increased in all
cohorts from the preperiod to postperiod. Similarly,
median household income fell in the postperiod for all
cohorts.
The county level race and ethnicity demographics
remained stable across time for all cohorts.
Regression results
The marginal effect for the interaction term between
the AF cohort and the postperiod represents the
difference-in-difference estimate (table 3). Compared
with the positive control cohort, the OAT initiation rate
increased on average 10-percentage points (p<0.01) for
the AF cohort in the postperiod. Controlling for patient
and hospital facility characteristics, this increase in OAT
initiation remained significant (11-percentage point
increase, p<0.01). Compared to the positive control
cohort, the rate of OAT initiation was not significantly
different in the negative control cohort. Oldest indivi-
duals (≥71 years) and those with the highest number of
comorbid conditions were less likely to initiate OAT.
Being at greater risk of acute ischaemic stroke (by
CHADS2 score) was not associated with greater OAT ini-
tiation. Greater number of outpatient primary care phy-
sicians claim preceding entry into the cohort was
associated with increased OAT initiation. Finally, residen-
tial distance from the admitting hospital was negatively
associated with OAT initiation.
Sensitivity test results
In sensitivity analyses (table 4), the difference-in-
difference estimate for the AF group was robust to alter-
nate definitions of OAT initiation. The combined phar-
macy claims, blood laboratory test and anticoagulation
management definition of OAT initiation yielded a
similar marginal effect of a nine-percentage point
increase (p<0.05) in OAT initiation for the treatment
group compared with the positive control cohort in the
postperiod. The marginal effect was smaller and non-
significant in the blood laboratory test and
Table 1 Proportion of cohort initiating oral anticoagulation therapy in preperiod and postperiod
Cohort Preperiod Postperiod
Difference p ValueN Proportion N Proportion
Eligible AF 1359 0.268 662 0.317 0.049 0.022
Positive control 1597 0.675 1111 0.620 −0.055 0.003
Negative control 302 0.238 204 0.206 −0.032 0.398
Difference-in-difference estimate (AF-positive control) 0.104
Difference-in-difference estimate (AF-negative control) 0.081
AF, atrial fibrillation.
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valve (+ control) PAF (− control) Eligible AF
Mechanical heart
valve (+ Control) PAF (− Control)
Sample size 1359 1597 302 662 1111 204
Patient characteristics
Age 77.9 (11.2) 65.0 (15.7) 71.2 (12.9) 76.7 (11.3) 65.4 (15.3) 70.6 (12.6)
Male 40.5 41.3 53.3 38.7 40.8 57.4
Rural 9.7 10.2 9.3 12.3 10.5 11.8
CHF 29.7 18.8 32.5 23.0 27.1 34.3
Hypertension 94.7 68.1 82.8 96.2 76.8 85.8
Diabetes mellitus 45.3 26.5 39.4 45.5 35.2 39.7
Ischaemic stroke 23.7 18.8 21.5 35.5 31.1 29.4
CHADS2 score 2.9 (1.0) 1.8 (1.5) 2.4 (1.5) 3.0 (1.1) 2.3 (1.7) 2.6 (1.6)
Charlson index 2.0 (1.7) 1.4 (1.6) 2.3 (2.0) 2.1 (1.7) 1.9 (2.0) 2.7 (2.3)
Haemorrhagic stroke 0 1.8 0.7 0 1.6 2
Gastrointestinal bleed 0 4.1 2.0 0 8.5 5.4
Falls risk 0 7.5 8.9 0 13.8 7.4
Cirrhosis 0 2.9 2 0 5.3 4.9
Dementia 0 1.8 2.3 0 2.3 2.5
Terminal illness 0 7.4 6.3 0 7.5 6.9
Relative OAT contraindications 0* 0.5 (0.7) 0.4 (0.7) 0* 0.7 (0.9) 0.6 (0.9)
Outpatient visits 3.1 (3.6) 4.1 (6.1) 4.0 (7.2) 3.5 (3.6) 4.8 (5.6) 4.0 (5.5)
Facility characteristics
Rural hospital 4.7 4.4 2.4 5.8 6.0 3.1
Primary stroke centre 19.2 21.7 31.1 45.8 43.8 50.5
Participates in GWTG 48.6 50.5 47.4 59.2 56.3 63.7
Hospital bed size 449 (311) 464 (309) 525 (322) 461 (307) 460 (310) 506 (324)
Distance residence hospital (miles) 21.7 (82.2) 23.9 (76.7) 22.9 (57.9) 20.1 (48.0) 18.4 (53.4) 18.5 (28.7)
County characteristics
Caucasian (%) 68.9 (15.3) 68.3 (15.0) 68.5 (14.5) 68.5 (15.1) 68.7 (15.0) 67.6 (15.2)
Per cent African-American (%) 21.4 (13.2) 21.8 (13.2) 21.6 (12.6) 22.0 (13.3) 21.4 (13.3) 22.5 (14.2)
Per cent American Indian 1.4 (5.2) 1.5 (5.2) 1.4 (4.8) 1.3 (4.7) 1.5 (5.1) 1.2 (2.0)
Asian 2.0 (1.9) 2.2 (2.0) 2.2 (2.0) 1.9 (1.9) 2.1 (2.0) 2.2 (2.0)
Hispanic 7.9 (3.6) 8.0 (3.7) 8.0 (3.3) 8.0 (3.7) 8.1 (3.6) 8.3 (4.4)
General practitioners 62.6 (67.8) 68.1 (72.1) 73.5 (76.1) 68.4 (79.8) 73.5 (87.0) 73.6 (80.9)
Cardiovascular specialists 17.0 (21.6) 18.6 (22.9) 20.7 (24.2) 17.6 (23.2) 19.4 (24.8) 19.6 (23.7)
3 year average death cerebrovascular disease 106.5 (90.0) 113.2 (96.8) 119.3 (101.3) 107.0 (91.7) 112.7 (105) 108.7 (93.7)
County Median Hhld income (1000s) 44.6 (9.4) 45.1 (9.6) 46.6 (10.2) 43.5 (9.6) 44.7 (10.0) 44.7 (10.5)
Unemployment rate 5.2 (1.4) 5.4 (1.5) 5.5 (1.7) 10.7 (2.1) 10.7 (2.1) 10.5 (2.3)
*Inclusion in AF treatment group conditional on value of zero for this variable.
(), SD.
AF, atrial fibrillation; CHADS2, C—congestive heart failure, H—hypertension, A—>75 years, D—diabetes mellitus, S—prior stroke or stroke symptoms; CHF, congestive heart failure; GWTG, Get





















anticoagulation management only definition of OAT ini-
tiation. Other associations were similar to that observed
in the primary analysis. We also found a strong marginal
effect on OAT initiation for an outpatient-only interven-
tion cohort and the combined inpatient–outpatient
cohort. Finally, multiple model specifications with alter-
nate functional form and additional control covariates
resulted in similar findings as our primary analysis (see
web-only table A.5).
DISCUSSION
We examined the association between the Joint
Commission revising NPSGs and OAT initiation among
privately insured individuals with new onset AF.
Compared with the positive control cohort, the revised
Joint Commission NPSGs were associated with a
10-percentage point increase in the rate of OAT
initiation among individuals with new onset AF. The
negative association between age and OAT initiation as
well as number of comorbidities and OAT initiation are
consistent with what has been previously described in
the literature.45 The relative lack of association of
increasing CHADS2 scores and OAT initiation is also
consistent with prior work and is hypothesised to be sec-
ondary to increased comorbidities associated with
increasing CHADS2 score that may discourage a clin-
ician from initiating OAT.46
The strong positive association between NPSGs and
the outpatient cohort in our sensitivity analysis suggest
an indirect effect of NPSGs as well. The rate of OAT ini-
tiation in the positive control cohort was smaller than
anticipated, and decreased between preperiod and
postperiod.
The relatively low-OAT initiation in the positive
control (perceived very high risk) cohort and the
Table 3 Estimated marginal effects of policy changes, patient characteristics and inpatient facility characteristics on oral
anticoagulation therapy initiation
Adjusted for patient characteristics
Adjusted for patient and facility
characteristics
Adjusted results
Postperiod −0.04* (−0.07 to −0.01) −0.03* (−0.06 to −0.00)
Treatment group −0.39*** (−0.43 to −0.35) −0.38*** (−0.42 to −0.34)
Negative control −0.45*** (−0.54 to −0.36) −0.45*** (−0.54 to −0.36)
Post-treatment 0.10** (0.04 to 0.17) 0.11** (0.04 to 0.18)
Post-negative control −0.03 (−0.19 to 0.13) −0.03 (−0.19 to 0.13)
Patient characteristics
18–40 years 0.03 (−0.03 to 0.09) 0.03 (−0.02 to 0.09)
61–70 years −0.01 (−0.04 to 0.02) −0.01 (−0.04 to 0.02)
71+ years −0.10*** (−0.13 to −0.07) −0.10*** (−0.14, −0.07)
Gender (male) 0.02* (0.00 to 0.04) 0.03** (0.01 to 0.05)
Charlson (0) 0.01 (−0.03 to 0.06) 0.01 (−0.03 to 0.05)
Charlson (2) −0.04* (−0.07 to −0.00) −0.04* (−0.07 to −0.00)
Charlson (3–4) −0.02 (−0.06 to 0.03) −0.01 (−0.06 to 0.03)
Charlson (5+) −0.13*** (−0.17 to −0.09) −0.12*** (−0.17 to −0.08)
CHADS2 (0–1) −0.02 (−0.05 to 0.02) −0.01 (−0.05 to 0.03)
CHADS2( 3–4) −0.05* (−0.09 to −0.01) −0.04* (−0.08 to −0.00)
CHADS2 (5+) −0.04 (−0.11 to 0.04) −0.03 (−0.10 to 0.04)
Rural 0.02 (−0.03 to 0.06) 0.01 (−0.05 to 0.07)
Micropolitan 0.01 (−0.03 to 0.04) −0.00 (−0.05 to 0.04)
0 pre-event visits −0.05* (−0.09 to −0.00) −0.04 (−0.09 to 0.00)
2+ pre-event visits 0.06*** (0.03 to 0.09) 0.05*** (0.02 to 0.08)
Facility characteristics
Primary stroke centre −0.01 (−0.06 to 0.04)
GWTG participation −0.01 (−0.03 to 0.02)
4–99 beds −0.04 (−0.09 to 0.00)
500+ beds −0.04 (−0.08 to 0.00)
25+ miles −0.10*** (−0.16 to −0.05)
Rural provider 0.07 (−0.01 to 0.16)
Micropolitan provider 0.04 (−0.01 to 0.09)
Observations 5235 5235




CHADS2, C—congestive heart failure, H—hypertension, A—>75 years, D—diabetes mellitus, S—prior stroke or stroke symptoms, GWTG,
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Table 4 Estimated marginal effects of sensitivity analyses in alternate outcome definitions, outpatient only cohort and combined inpatient/outpatient cohorts
OAT-RX and
OAT-laboratories OAT-laboratories OAT-outpatients OAT-all
18–40 years 0.01 (−0.04 to 0.07) 0.01 (−0.03 to 0.06) −0.02 (−0.07 to 0.03) 0.01 (−0.03 to 0.04)
61–70 years −0.02 (−0.04 to 0.01) −0.18*** (−0.21 to −0.14) 0.02 (−0.01 to 0.06) 0.01 (−0.02 to 0.04)
71+ years −0.12*** (−0.16 to −0.09) −0.38*** (−0.43 to −0.34) −0.05* (−0.09 to −0.01) −0.09*** (−0.11 to −0.06)
Gender (male) 0.02 (−0.00 to 0.04) 0.01 (−0.01 to 0.03) 0.06*** (0.03 to 0.08) 0.04*** (0.02 to 0.06)
Charlson (0) 0.02 (−0.02 to 0.06) 0.03 (−0.00 to 0.05) 0.03 (−0.01 to 0.07) 0.01 (−0.01 to 0.04)
Charlson (2) −0.03 (−0.06 to 0.01) −0.02 (−0.05 to 0.01) −0.04 (−0.08 to 0.01) −0.05** (−0.08 to −0.01)
Charlson (3–4) −0.00 (−0.05 to 0.04) −0.04* (−0.07 to −0.00) −0.05 (−0.09 to 0.00) −0.05** (−0.08 to −0.01)
Charlson (5+) −0.12*** (−0.16 to −0.07) −0.07*** (−0.11 to −0.03) −0.11*** (−0.17 to −0.05) −0.13*** (−0.17 to −0.09)
CHADS2 (0–1) −0.00 (−0.04 to 0.04) 0.02 (−0.01 to 0.05) 0.02 (−0.02 to 0.06) 0.00 (−0.03 to 0.03)
CHADS2( 3–4) −0.04* (−0.08 to −0.00) −0.01 (−0.03 to 0.02) −0.01 (−0.05 to 0.03) −0.03* (−0.05 to −0.00)
CHADS2 (5+) −0.02 (−0.08 to 0.04) −0.04 (−0.10 to 0.02) −0.04 (−0.10 to 0.03) −0.04 (−0.09 to 0.01)
Rural −0.00 (−0.07 to 0.06) −0.04* (−0.08 to −0.01) −0.05 (−0.11 to 0.01) −0.03 (−0.07 to 0.01)
Micropolitan −0.01 (−0.06 to 0.04) −0.03** (−0.05 to −0.01) 0.00 (−0.05 to 0.05) −0.01 (−0.04 to 0.02)
Postperiod −0.02 (−0.05 to 0.01) 0.03** (0.01 to 0.05) 0.01 (−0.02 to 0.04) −0.01 (−0.03 to 0.01)
Treatment group −0.38*** (−0.42 to −0.34) −0.14*** (−0.18 to −0.10) −0.44*** (−0.50 to −0.39) −0.42*** (−0.46 to −0.38)
Post-treatment 0.09* (0.02 to 0.16) 0.03 (−0.03 to 0.09) 0.17*** (0.09 to 0.25) 0.14*** (0.08 to 0.19)
Negative control −0.44*** (−0.53 to −0.36) −0.21*** (−0.27 to −0.15) −0.49*** (−0.64 to −0.34) −0.49*** (−0.57 to −0.40)
Post-negative control −0.03 (−0.19 to 0.13) −0.02 (−0.11 to 0.08) 0.09 (−0.10 to 0.29) 0.02 (−0.10 to 0.14)
0 prediagnosis visits −0.05* (−0.09 to −0.00) −0.06*** (−0.10 to −0.03) 0.09** (0.03 to 0.14) 0.02 (−0.01 to 0.06)
2+ prediagnosis visits 0.05*** (0.02 to 0.08) 0.04*** (0.02 to 0.07) 0.08*** (0.04 to 0.12) 0.06*** (0.03 to 0.08)
Primary stroke centre −0.01 (−0.06 to 0.04) −0.02 (−0.05 to 0.00)
GWTG participation −0.01 (−0.04 to 0.01) −0.00 (−0.03 to 0.02)
4–99 beds −0.04* (−0.09 to −0.00) 0.01 (−0.02 to 0.04)
500+ beds −0.03 (−0.07 to 0.01) −0.01 (−0.05 to 0.03)
25+ miles −0.10*** (−0.15 to −0.05) −0.04*** (−0.06 to −0.02)
Rural provider 0.08 (−0.00 to 0.17) 0.05 (−0.01 to 0.10) 0.12** (0.04 to 0.20) 0.11*** (0.05 to 0.17)
Micropolitan provider 0.05* (0.00 to 0.09) 0.04* (0.00 to 0.08) 0.01 (−0.04 to 0.06) 0.04* (0.01 to 0.07)
Inpt Index Claim −0.03** (−0.05 to −0.01)
Observations 5235 5235 4694 9380




CHADS2, C—congestive heart failure, H—hypertension, A—>75 years, D—diabetes mellitus, S—prior stroke or stroke symptoms; GWTG, Get With The Guidelines; Inpt, inpatient; OAT, oral





















intervention cohort, as well as the higher than expected
OAT initiation in the negative control (perceived low
risk) cohort, are interesting. This finding may reflect the
nature of health insurance claims data, which may miss
prescription claims (especially given the availability of
low-cost mediations at retail stores). However, our mea-
sured rates of OAT initiation in the AF cohort are con-
sistent with prior studies.44 While we believe
underutilisation of OAT among incident AF and paroxys-
mal AF patients is evident in our findings, this underutil-
isation should be reported with caution given the
inherent limitations of using claims data. We view our
results, not as an indictment suggesting poor quality of
care for new onset AF, but rather as an examination of
positive trends in guideline concordant care for patients
with incident AF following policy change, and an
absence of unintended negative effects on care. We also
note that the rate of anticoagulation observed in the
positive control may represent a realistic target rate for
incident AF and patients with paroxysmal AF when using
claims data.
The study has several strengths. First, the use of per-
ceived very high-risk and perceived low-risk control
groups allow for greater mitigation of potential time bias
between the preperiod and postperiod that is common
in observational studies. We are not aware of published
OAT initiation rates for individuals with mechanical
heart valves or significant thromboembolism. Using this
group as a benchmark sheds new light on previous
observational studies. Second, using a statewide claims
database with approximately one million privately
insured state workers, spouses, dependents and retirees
increases the generalisability of our findings. Third,
linking with the Area Resource File and OSCAR data-
bases provides a rich array of county and hospital facility
control variables, respectively. Fourth, we included mul-
tiple controls for comorbid conditions and relative con-
traindications to OAT. Finally, the clustering of
individuals within the hospital in which they received
treatment mitigates potential effects of outlier hospitals
on the population-averaged effect of the policy
change.40
There are several limitations of our study. First, we
used a quasi-experimental observational study design.
Without randomisation, we cannot eliminate threats to
internal validity such as regression to the mean, history
and instrumentation. For example, unmeasured differ-
ences in all cohorts between preperiod and postperiod
may have confounded our findings. Second, because we
used claims data, we may have misclassified OAT initi-
ation, especially with the popularity of low-cost generic
OAT that could be purchased without billing the
insurer.43 We have no reason to suspect differential bias
in pharmacy claims for warfarin across the three cohorts
regarding OAT initiation. Furthermore, if present, this
trend may increase with time, which would bias OAT ini-
tiation downwards in the postperiod; this may help
explain the slight decrease in OAT initiation among the
guideline-positive cohort. Importantly, our sensitivity
analyses suggested that findings were robust to alterna-
tive definitions of OAT initiation. Third, we could not
control for individual level race, ethnicity or socio-
economic status. However, we controlled for county level
indicators of race and socioeconomic status to mitigate
these potential effects. Fourth, most members of our
cohorts had employee-sponsored group health insur-
ance; results may not generalise to publicly insured
populations. Notably, our cohorts included a large pro-
portion of retired Medicare enrollees utilising both their
Medicare and NCSHP benefits, which serves to enhance
generalisability to Medicare beneficiaries. Finally, new
medications for OAT were approved for reduction of
stroke risk in patients with AF in late 2010. We purposely
limited our study window to exclude these medications
which, while more expensive than warfarin, do not
require the same frequency of laboratory monitoring
and titration of dosage.
CONCLUSION
Our findings show that following NPSGs concerning
anticoagulation, lower rates of anticoagulation among
incident eligible patients with AF were not observed.
Rather when compared with control groups which
declined in the rate of anticoagulation, rates of anticoa-
gulation increased among eligible patients with incident
AF. OAT initiation should be re-examined with add-
itional years of data, broader geographic representation
and the inclusion of novel anticoagulation agents to
support or refute our findings. Our work demonstrates
the direct (in primary analysis of patients with incident
inpatient diagnosed AF) and indirect (in sensitivity ana-
lysis of patients with incident outpatient diagnosed AF)
changes in anticoagulation practice co-occurring with
changes in policies of healthcare regulatory agencies via
patient safety and quality improvement initiatives.
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